A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

This study is testing a new drug called EIK1004 (IMP1707), which targets a protein called PARP1, in people with advanced solid tumors including breast cancer, ovarian cancer, prostate cancer, and pancreatic cancer. **You may be eligible if...** - You are 18 or older with advanced breast, ovarian, fallopian tube, peritoneal, prostate, or pancreatic cancer - You have already received prior chemotherapy and/or hormone therapy appropriate for your cancer type - You are in good overall health (able to care for yourself) - Your organs (liver, kidneys, bone marrow) are functioning adequately - You have a life expectancy of at least 12 weeks **You may NOT be eligible if...** - You have not received prior required treatments for your cancer type - Your overall health or organ function is too poor Talk to your doctor to see if this trial is right for you.